This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection. Introduction Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women. Methods Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 1:1 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality. Results A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users. Conclusion Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.
C1 [Atmaca, A.] Samsun Ondokuz Mayis Univ, Sch Med, Dept Endocrinol & Metab, Samsun, Turkey.
[Demirci, I.; Haymana, C.] Univ Hlth Sci Turkey, Gulhane Training & Res Hosp, Dept Endocrinol & Metab, Ankara, Turkey.
[Tasci, I.] Univ Hlth Sci Turkey, Gulhane Sch Med, Dept Internal Med, Ankara, Turkey.
[Tasci, I.; Sonmez, A.] Univ Hlth Sci Turkey, Gulhane Training & Res Hosp, Ankara, Turkey.
[Sahin, I.] Malatya Inonu Univ, Sch Med, Dept Endocrinol & Metab, Malatya, Turkey.
[Cakal, E.] Univ Hlth Sci Turkey, Diskapi Yildirim Beyazit Training & Res Hosp, Sch Med, Dept Endocrinol & Metab, Ankara, Turkey.
[Ata, N.] Minist Hlth, Dept Strategy Dev, Ankara, Turkey.
[Dagdelen, S.; Unluturk, U.] Hacettepe Univ, Sch Med, Dept Endocrinol & Metab, Ankara, Turkey.
[Salman, S.] Med Clin, Dept Endocrinol & Metab, Istanbul, Turkey.
[Emral, R.; Sahin, M.] Ankara Univ, Sch Med, Dept Endocrinol & Metab, Ankara, Turkey.
[Celik, O.] Minist Hlth, Publ Hosp Gen Directorate, Ankara, Turkey.
[Demir, T.] Dokuz Eylul Univ, Sch Med, Dept Endocrinol & Metab, Izmir, Turkey.
[Ertugrul, D.] Univ Hlth Sci Turkey, Kecioren Training & Res Hosp, Sch Med, Dept Endocrinol & Metab, Ankara, Turkey.
[Caglayan, M.] Ankara Prov Hlth Directorate, Ankara, Turkey.
[Satman, I.] Istanbul Univ, Sch Med, Dept Endocrinol & Metab, Istanbul, Turkey.
[Satman, I.] Turkish Inst Publ Hlth & Chron Dis, Istanbul, Turkey.
[Sonmez, A.] Univ Hlth Sci Turkey, Gulhane Sch Med, Dept Endocrinol & Metab, Ankara, Turkey.